Abstract: Improved organophotoreceptor comprises an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: (a) a charge transport material having the formula where R1, R2, R3, and R4 are, independently, H, an alkyl group, an alkaryl group, or an aryl group; X1 and X2 are, independently, a linking group having the formula —(CH2)m—, branched or linear, where m is an integer between 1 and 20, inclusive, and one or more of the methylene groups is optionally replaced by O, S, C?O, O?S?O, a heterocyclic group, an aromatic group, urethane, urea, an ester group, a NR5 group, a CHR6 group, or a CR7R8 group where R4, R5, R6, and R7 are, independently, H, hydroxyl group, thiol group, an alkyl group, an alkaryl group, a heterocyclic group, or an aryl group; and Y1, Y2, and Y3 are, independently, an arylamine group; and (b) a charge generating compound.

Abstract: This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof.

Abstract: An organophotoreceptor that includes: (a) a charge transport compound having the formula where n is an integer between 2 and 6, inclusive; R1 is an aryl group; R2 is a sulfolanyl group; a pyrrolyl group; a tetrazolyl group; a benzotriazolyl group; a stilbenyl group; an alkylsulfonylphenyl group, an arylsulfonylphenyl; a pyrazolyl group; or group A, where A is with the proviso that when R2 is an alkylsulfonylphenyl group or an arylsulfonylphenyl, R1 may be hydrogen, an alkyl group, or an aryl group; X is an alkylene linking group as described in the specification; and Y is a bond, C, N, O, S, a —(CH2)p— group where p is an integer between 0 and 10, an aryl group, a cycloalkyl group, a cyclosiloxyl, a heterocyclic group, or a CR7 group where R7 is H, alkyl group, or aryl group; (b) a charge generating compound; and (c) an electrically conductive substrate.

Abstract: Improved organophotoreceptor comprises an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: (a) a charge transport material having the formula where n is an integer between 3 and 6; R1 and R2 are, each independently, H, an alkyl group, an alkenyl group, an aromatic group, or a heterocyclic group; R3, R4, and R5 are, each independently, H, thiol, hydroxyl, carboxyl, an amino group, a halogen, nitro, cyano, an alkyl group, an alkenyl group, an aromatic group, a heterocyclic group, or a part of a ring group; X1 and X2 are, each independently, a linking group; Y comprises an arylamine group; and Z is a bridging group; and (b) a charge generating compound. Corresponding electrophotographic apparatuses and imaging methods are described.

Abstract: There is provided a charge transport material which can easily be coated to form a film, is less likely to be crystallized during or after film formation, has excellent charge transport capability, and high applicability to electronic devices. A charge transport monomer comprising conventional CBP with a specific substituent introduced thereinto is polymerized to prepare a polymer which is brought to a charge transport material comprising this polymer.

Abstract: This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof.

Abstract: A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. When the compound is obtained from a carbon acid with a pKa less than about 10, it provides vascular relaxing effect when used at micromolar concentrations and this activity is potentiated by glutathione to be obtained at nanomolar concentrations. When the compound is obtained from a carbon acid with a pKa ranging from about 15 to 20, vascular relaxing effect is obtained at nanomolar concentrations without glutathione. In another embodiment, a biocompatible polymer incorporates a C-nitroso moiety.

Abstract: The present invention relates to novel compounds useful as electronic hole transport materials, and to compositions and electronic devices comprising at least one layer containing the compositions.

Abstract: Disclosed herein are a gelling agent composed of an isoleucine derivative having a carbazolyl group, and a process for preparing a gelling agent, which comprises reacting an isoleucine derivative having a specific skeletal with a compound having a carbazolyl group in the presence of dichloromethane and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride to obtain an isoleucine derivative having a carbazolyl group.

Abstract: Improved organophotoreceptor comprises an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: (a) a charge transport material having the formula where R1 and R2 are, independently, H, an alkyl group, an alkaryl group, or an aryl group; X is a linking group having the formula —(CH2)m—, branched or linear, where m is an integer between 1 and 20, inclusive, and one or more of the methylene groups is optionally replaced by O, S, C?O, O?S?O, a heterocyclic group, an aromatic group, urethane, urea, an ester group, a NR3 group, a CHR4 group, or a CR5R6 group where R3, R4, R5, and R6 are, independently, H, hydroxyl group, thiol group, an alkyl group, an alkyl group, a heterocyclic group, or an aryl group; V comprises a vinyl ether group; and Z comprises an (N,N-disubstituted)arylamine group, such as a carbazole group, a julolidine group, or a p-(N,N-disubstituted)arylamine group; and (b) a charge generating compound.

Abstract: This invention relates to a novel organophotoreceptor that includes a photoconductive layer having a) a novel charge transport compound having the formula ?where R1 is a carbazole group, a julolidine group, or a p-(N,N-disubstituted)arylamine, R2, R3, R4, R5 and R6 are, independently, an alkyl group or an aryl group, R7 and R8 are, independently, hydrogen, an alkyl group, or an aryl group, X is oxygen, sulfur, or a NR? group where R? is hydrogen, an alkyl, or an aryl group, and Y is a trivalent aryl group; (b) a charge generating compound; and wherein the at least one photoconductive layer is carried on an electrically conductive substrate.

Abstract: Improved organophotoreceptors comprise: (a) a charge transport compound having the formula where n is an integer from 0 to 1; X is an (N,N-disubstituted)arylamine group; Ar is an aryl group or a heterocyclic group; A is a first linking group with the formula —(CH2)p— which can be branched or linear, where p is an integer from 3 to 20 inclusive; and B is a second linking group having the formula -Q-Z-Q?-, where Q and Q? are, independently, O, S, or NR1; wherein when Q or Q? is NR1 or Q=O and Q?=S, Z comprises an aryl group, and wherein when Q=Q?=S or Q=Q?=O, Z comprises a multi-ring conjugated group or Y—W—Y?, where the groups R1, Y, W, and Y? are defined in the specification; (b) a charge generating compound; and (c) an electrically conductive substrate over which said charge transport compound and said charge generating compound are located.

Abstract: Improved organophotoreceptor comprises an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: (a) a charge transport material having the formula ?where n is an integer between 2 and 6, inclusive; R1 and R2 are, independently, H, halogen, carboxyl, hydroxyl, thiol, cyano, nitro, aldehyde group, ketone group, an ether group, an ester group, a carbonyl group, an alkyl group, an alkaryl group, or an aryl group; X is a linking group having the formula —(CH2)m—, branched or linear, where m is an integer between 0 and 20, inclusive, and one or more of the methylene groups can be optionally replaced by O, S, C?O, O?S?O, urethane, urea, an ester group, a NR3 group, a CHR4 group, or a CR5R6 group where R3, R4, R5, and R6 are, independently, H, an alkyl group, an alkaryl group, a heterocyclic group, or an aryl group; Y comprises a bond, C, N, O, S, a branched or linear —(CH2)p— group where p is an integer between 0 and 1

Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a disorder relating to or affected by the 5-HT6 receptor.

Abstract: Compounds of the formulae I, II, III, IV and V wherein R1 i.a. is C4-C9cycloalkanoyl, C1-C12alkanoyl, C4-C6alkenoyl, or benzoyl; R2 is for example phenyl, C1-C20alkyl, C3-C8cycloalkyl, C2-C20alkanoyl, or benzoyl; Ar1 is R4S-phenyl or NR5R6-phenyl, each of which optionally is substituted; or Ar1 i.a. is optionally substituted; or Ar1 is naphthyl or anthracyl each of which is unsubstituted or substituted; or Ar1 is benzoyl, naphthalenecarbonyl, phenanthrenecarbonyl, anthracenecarbonyl or pyrenecarbonyl, each of which is unsubstituted or substituted, or Ar1 is 3,4,5-trimethoxyphenyl, phenoxyphenyl or biphenyl; Ar2 i.a.

Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to ?4 integrin receptors and thereby inhibit binding of ligands for ?4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with ?4 integrins or their ligands.

Abstract: The invention concerns a process for the preparation of N-aryl-aza-heterocycles of the general formula I by reaction of aza-heterocycles with activated aryl halides with use of caesium carbonate without addition of further catalysts at room temperature.

Abstract: Compounds of formula useful for treating tumors, particularly mammary carcinoma and colon carcinoma.

Abstract: Improved organophotoreceptors have: (a) a charge transport compound having the formula where R1 and R2 are, independently, an (N,N-disubstituted) arylamine group, such as a julolidine group, a triphenyl amine group, or an N-substituted carbazole group; R3 and R4 are, independently, an alkylsulfonylphenyl group; and X is a linking group having the formula —(CH2)m—, branched or linear, where m is an integer between 0 and 20, inclusive, and one or more of the methylene groups is optionally replaced by an oxygen atom, a carbonyl group, urethane, urea, an ester group, a —NR5 group, a CHR6 group, or a CR7R8 group where R5, R6, R7, and R8 are, independently, H, an alkyl group, or aryl group; (b) a charge generating compound; and (c) an electrically conductive substrate over which the charge transport compound and the charge generating compound are located.

Abstract: An inhibitor for 20-hydroxyeicosatetraenoic acid production which comprises as the active ingredient a specific hydroxyformamidine derivative or a pharmacologically acceptable salt thereof. It is useful especially as a remedy for kidney diseases, cerebrovascular diseases, or circulatory diseases. The novel hydroxyformamidine derivative or pharmacologically acceptable salt thereof is also provided.

Abstract: Improved organophotoreceptors have: (a) a charge transport compound having the formula: where R1 is hydrogen, a branched or linear alkyl group, a branched or linear unsaturated hydrocarbon group, an ether group, or an aryl group; and R2 and R3 independently have a structure of: in which Ar is selected form the group consisting of; R4 is a hydrogen, or an aromatic group; (b) a charge generating compound; and (c) an electrically conductive substrate.

Abstract: This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof.

Abstract: A pigment's etheramine sulfonic acid salt is described. Also described is a method for enhancing the performance of a pigment composition containing an organic pigment, comprising enhancing the dispersion of said pigment by adding to 100 parts of said pigment about 1 to 40 parts of a pigment's etheramine sulfonic acid salt.

Abstract: A process useful for making ondansetron that comprises reacting a carbazolone in a reaction mixture comprising a carbazolone of formula (2), a formaldehyde or precursor thereof, and an amine of formula (3) in a non-aqueous polar solvent and in the presence of a water binding agent. The reaction product(s) can be reacted with an amine of formula (5) to form ondansetron. The water binding agent can improve the yield and/or speed of the reaction.

Abstract: The present invention discloses novel aromatic azide derivatives and their bioconjugates for phototherapy of tumors and other lesions. The organic azides of the present invention are designed to absorb low-energy ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum. The phototherapeutic effect is caused by direct interaction of nitrene, the reactive intermediate produced upon photoexcitation of the aromatic azide, with the tissue of interest. The compounds of the present invention are administered to a patient, allowed to accumulate at the site of the tumor or other lesion, and are exposed to light in order to perform a phototherapeutic procedure.

Abstract: The invention relates to polymerisable charge transport compounds, their use as semiconductors or charge transport materials, in optical, electrooptical or electronic devices like for example organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in plotovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the polymerisable charge transport compounds.

Abstract: This invention relates to a novel crystalline solid of carvedilol or a solvate thereof, to processes for its preparation, to compositions containing it and to its use in medicine. This invention further relates to a novel process for preparing a crystalline solid of carvedilol Form II.

Abstract: Organic dye molecular materials prepared by coupling existing organic chromophore molecules to benzene or carbazole derivatives and nonlinear optical polymeric compounds having polyimide repeating units coupled with the organic dye molecular material are provided. The organic dye molecular material coupled to a polymer main chain in the preparation of the nonlinear optical polymeric compound has one of the following formula: where X1 is carbon, oxygen, sulfur, nitrogen, ester (CO2), or amide (CONR1), where R1 is an alky or phenyl group having 1 to 6 carbon atoms, D is an organic chromophore molecule, and n is an integer from 1 to 10.

Abstract: The invention provides compounds of formula I for use in treating conditions in which 5-HT6 receptors are involved such as in anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy, and other CNS disorders.

Abstract: A process for the preparation heterocyclic indene analogs, especially with the preparation of 4-hydroxycarbazole or N-protected 4-hydroxycarbazole, involves cyclocarbonylation followed by saponification. This process avoids high temperatures and high catalyst loadings.

Abstract: This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof.

Abstract: This invention relates to a novel crystalline from of Carvedilol, and to the use of pharmaceutical compositions thereof.

Abstract: The invention relates to novel carbazole derivatives, their use for the preparation of a pharmaceutical composition for the treatment of eating and metabolic disorders such as obesity, bulimia nervosa, anorexia nervosa, of sleep disturbance, of morphine withdrawal symptoms and of epileptic seizures, a pharmaceutical composition containing them and a process for preparing them.

Abstract: Organophotoreceptors comprise an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: a) a charge transport compound having the formula where R1 and R2 are, independently, hydrogen, an alkyl group, a heterocyclic group, an alkaryl group or an aryl group; X is an aromatic group; Y is an (N,N-disubstituted) arylamine group, such as a (N,N-disubstituted) arylamine group, a carbazole group or a julolidine group; Z is (CH2)m group where m is an integer between 1 and 30 where one or more of the methylene groups is optionally replaced by O, S, C═O, O═C—O, O═C—NR3, sulfoxide, sulfate, phosphate, an aryl group, urethane, urea, a NR4 group, a CHR5 group, or a CR6R7 group where R3, R4, R5, R6, and R7 are, independently, H, hydroxyl, thiol, an amine group, an alkyl group, a heterocyclic group, an alkaryl group, or an aryl group; and E is an epoxy group; and (b) a charge generating co

Abstract: The present invention provides a thermodynamically stable modification of (±)1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole and pharmacologically acceptable salts or optically active forms thereof as well as processes for their preparation and pharmaceutical compositions containing one or more of them.

Abstract: Organic dye molecular materials prepared by coupling existing organic chromophore molecules to benzene or carbazole derivatives and nonlinear optical polymeric compounds having polyimide repeating units coupled with the organic dye molecular material are provided.

Abstract: This invention relates to a novel crystalline solid of carvedilol or a solvate thereof, to processes for its preparation, to compositions containing it and to its use in medicine. This invention further relates to a novel process for preparing a crystalline solid of carvedilol Form II.

Abstract: This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof.

Abstract: A process for the preparation of tricyclic amino alcohol derivatives including 2-[N-[2-(9H-carbazol-2-yloxy)ethyl]]amino-1-[(3-methylsulfonylamino)phenyl]ethanol useful in the treatment of diabetes, obesity, hyperlipidemia and so on; and intermediates as represented by formula (5) or (6) or the like useful in the preparation, wherein R11 is hydrogen or the like; and *1 represents an asymmetric carbon atom. 2-Halo-1-(3-nitrophenyl)ethanone derivatives and 1-(3-nitrophenyl)oxirane derivatives, which are intermediates for the preparation of tricyclic amino alcohol derivatives, are easy of purification, and particularly optically active 1-(3-nitrophenyl)oxirane derivatives are effective in enhancing the optical purities of the final products.

Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a disorder relating to or affected by the 5-HT6 receptor.

Abstract: This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydrocarbazole derivatives as well as a process for the production of the new tetrahydrocarbazole derivatives are also provided. Moreover, this invention relates to the administration of tetrahydrocarbazole derivatives for treating pathologic conditions that are mediated by GPCR, especially for inhibiting GnRH, in mammals, especially humans, who require such an administration, as well as the use of tetrahydrocarbazole derivatives for the production of a pharmaceutical agent for treating GPCR-mediated pathologic conditions, especially for inhibiting GnRH.

Abstract: This invention relates to a novel organophotoreceptor that includes:

Abstract: A process for the preparation of tricyclic amino alcohol derivatives including 2-[N-[2-(9H-carbazol-2-yloxy)ethyl]]amino-1-[(3-methylsulfonylamino)phenyl]ethanol useful in the treatment of diabetes, obesity, hyperlipidemia and so on; and intermediates as represented by formula (5) or (6) or the like useful in the preparation, wherein R11 is hydrogen or the like; and *1 represents an asymmetric carbon atom. 2-Halo-1-(3-nitrophenyl)ethanone derivatives and 1-(3-nitrophenyl)oxirane derivatives, which are intermediates for the preparation of tricyclic amino alcohol derivatives, are easy of purification, and particularly optically active 1-(3-nitrophenyl)oxirane derivatives are effective in enhancing the optical purities of the final products.

Abstract: This invention provides novel compounds possessing antibacterial and/or antifungal and/or antitumor activity. Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.

Abstract: Charge transport compounds are described that have a multiple number of hydrazone-bridged heterocyclic groups (especially julolidine groups, carbazole groups, triarylamine groups and (N,N-disubstituted)arylamine groups such as dialkarylamine groups (e.g. dimethylphenylamine; methylethylphenylamine, dipropylphenylamine, ethylepropylphenylamine, ethylbutylnaphthylamine, etc.), alkyldiarylamine groups (e.g. methyldiphenylamino, ethyldiphenylamino, etc), and triarylamino groups (e.g., triphenyl amino, trinaphthylamino, etc)) connected by a central bridging group.

Abstract: Improved organophotoreceptors have:

Abstract: This invention relates to a novel organophotoreceptor that includes: (a) a charge transport composition comprising molecules having the formula 1

Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.

Abstract: The present invention relates to new derivatives of amino acids and their use as medicaments.

Abstract: A novel calcium receptor active compound having the formula is provided: